SCHEMBL1124189

SCHEMBL1124189

CCOC(=O)Cc1ccc(N=C=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4Z1 Q86W10 4/20 0.58
TSHR P16473 2/20 0.50
CYP3A4 P08684 1/20 0.50
MAPT P10636 2/20 0.46
CYP4F2 P78329 2/20 0.45
CYP4A11 Q02928 2/20 0.45
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP4F11 Q9HBI6 1/20 0.41
CYP4F12 Q9HCS2 1/20 0.41
TBXAS1 P24557 1/20 0.40
LIPE Q05469 1/20 0.40
FDFT1 P37268 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3765043 0.86 CYP4Z1 (0.57) CYP4Z1TSHRMAPTCYP4F2CYP4A11
Urea SCHEMBL28118576 0.85 CYP4Z1 (0.45) CYP4Z1TSHRCYP3A4MAPTCYP4F2
SCHEMBL3306612 0.83 CYP4F2 (0.59) CYP4Z1TSHRCYP3A4MAPTCYP4F2
SCHEMBL68851 0.82 CYP4Z1 (0.62) CYP4Z1TSHRMAPTCYP4F2CYP4A11
SCHEMBL11158755 0.82 CYP4Z1 (0.62) CYP4Z1TSHRCYP3A4CYP4F2CYP4A11
SCHEMBL11626840 0.82 CYP4Z1 (0.44) CYP4Z1CYP3A4MAPTCYP4F2CYP4A11
SCHEMBL12062874 0.81 CYP4Z1 (0.63) CYP4Z1TSHRMAPTCYP4F2CYP4A11
SCHEMBL13224167 0.81 TSHR (0.47) CYP4Z1TSHRCYP3A4CYP4F2CYP4A11
SCHEMBL8870777 0.80 ALDH1A1 (0.68) TSHRCYP3A4ALDH1A1LIPEKMT2A
SCHEMBL12369128 0.79 CYP3A4 (0.49) CYP4Z1TSHRCYP3A4MAPTCYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713378-A1 ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2026-03-25 EP disclosed
EP-3774961-B1 ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2025-01-15 EP disclosed
WO-2024236000-A1 ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2024-11-21 WO disclosed
EP-4464727-A1 ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2024-11-20 EP disclosed
US-20220363809-A1 POLYMERIZABLE COMPOSITIONS FOR PREPARING POLYISOCYANURATE-BASED PLASTICS HAVING EXTENDED WORKLIFE COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2022-11-17 US disclosed
US-11289238-B2 Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) 2022-03-29 US disclosed
CN-114040934-A Polymerizable composition for producing polyisocyanurate-based plastics having extended pot life 科思创知识产权两合公司 2022-02-11 CN disclosed
CN-112020525-A Adducts of amine catalysts for making isocyanurate polymers 科思创知识产权两合公司 2020-12-01 CN disclosed
CN-106232667-B Polyiso-ureas 巴斯夫欧洲公司 2020-01-07 CN disclosed
CN-103347860-A Nampt inhibitor ABBOTT LAB 2013-10-09 CN disclosed
EP-2640704-A1 NAMPT INHIBITORS Abbvie Inc. (US) 2013-09-25 EP disclosed
WO-2012067963-A1 NAMPT INHIBITORS ABBOTT LABORATORIES (US) 2012-05-24 WO disclosed
US-20120122924-A1 NAMPT INHIBITORS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
EP-2284157-A1 Quinolines useful in treating cardiovascular disease Wyeth (US) 2011-02-16 EP disclosed
US-7576215-B2 Quinolines and pharmaceutical compositions thereof WYETH (US) 2009-08-18 US disclosed
EP-1692111-A2 QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE Wyeth, A Corporation of the State of Delaware (US) 2006-08-23 EP disclosed
WO-2005058834-A2 QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE WYETH (US) 2005-06-30 WO disclosed
US-20050131014-A1 Quinolines useful in treating cardiovascular disease WYETH (US) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122924-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT CYP4Z1 4288/4885TSHR 3144/4885CYP3A4 4662/4885
US-20050131014-A1 Quinolines useful in treating cardiovascular disease NR1H2, NR1H3, SREBF1 CYP4Z1 806/4885TSHR 2030/4885CYP3A4 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.